NCT07024706
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07024706
Title Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab (MAVRiC)
Acronym MAVRiC
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | POL | ITA | IRL | ESP | CZE | AUT

Facility Status City State Zip Country Details
Research Site Boston Massachusetts 02215 United States Details
Research Site Charlotte North Carolina 28204 United States Details
Research Site Durham North Carolina 27705 United States Details
Research Site Horn 3580 Austria Details
Research Site Brno 625 00 Czechia Details
Research Site Hradec Kralova 50005 Czechia Details
Research Site Ostrava 708 502 Czechia Details
Research Site Dublin 7 Ireland Details
Research Site Dublin D08 NHY1 Ireland Details
Research Site Lugo 48022 Italy Details
Research Site Meldola 47014 Italy Details
Research Site Milan 20162 Italy Details
Research Site Padua 35128 Italy Details
Research Site Roma 00165 Italy Details
Research Site Rome 00168 Italy Details
Research Site Torino 10126 Italy Details
Research Site Bydgoszcz 85-168 Poland Details
Research Site Krakow 30-727 Poland Details
Research Site Lodz 93-513 Poland Details
Research Site Lublin 20-090 Poland Details
Research Site Warsaw 02-172 Poland Details
Research Site Warsaw 02-776 Poland Details
Research Site Barcelona 08041 Spain Details
Research Site Barcelona 8035 Spain Details
Research Site Granada 18014 Spain Details
Research Site Madrid 28031 Spain Details
Research Site Madrid 28034 Spain Details
Research Site Madrid 28041 Spain Details
Research Site Majadahonda 28222 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field